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ABSTRACT
Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on
work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately con-
trolled by topical treatments in a two-part, phase II, randomized control trial. The Work Productivity and Activity
Impairment – Atopic Dermatitis questionnaire was an exploratory end-point. Part A was a 12-week, placebo-con-
trolled study in which patients received s.c. nemolizumab 0.1, 0.5 or 2.0 mg/kg every 4 weeks or 2.0 mg/kg every
8 weeks. Part B was a 52-week extension in which all patients received active treatment. A total of 138 patients
had Work Productivity and Activity Impairment – Atopic Dermatitis data; 104 were employed at baseline. At week
12, patients receiving nemolizumab every 4 weeks showed greater mean (standard error) Work Productivity and
Activity Impairment – Atopic Dermatitis improvement (score reduction) from baseline versus placebo: Percent
Work Time Missed (0.1, 0.5 or 2.0 mg/kg vs placebo): –4.0% (3.9%), –1.7% (4.2%) and –1.6% (4.2%) versus 4.9%
(4.5%); Percent Impairment While Working, –15.8% (6.0%), –24.1% (6.5%) and –34.3% (6.4%) versus –16.5% (7.1%);
Percent Overall Work Impairment, –16.3% (6.0%), –23.1% (6.5%) and –34.5% (6.3%) versus –16.6% (7.1%); and Per-
cent Activity Impairment, –13.4% (5.3%), –23.5% (5.3%) and –41.9% (5.5%) versus –10.9% (5.7%). Improvements
were sustained through week 64. Nemolizumab-treated patients with moderate to severe atopic dermatitis
reported improvements in Work Productivity and Activity Impairment through week 64.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic, inflammatory, T-cell-medi-
ated skin disease associated with disseminated, intensely pru-
ritic skin lesions. Itching, the dominant clinical feature of AD,1–3
is mediated by the binding of the pro-inflammatory cytokine
interleukin (IL)-31 to IL-31 receptor A on sensory neurones4–6
and chronic pruritus exacerbates disease through the itch–
scratch cycle.7 Long-term symptom alleviation is a treatment
goal for this chronic condition; however, treatment options are
limited for patients with AD unresponsive to topical therapies,
such as the corticosteroids and calcineurin inhibitors that form
the mainstay of therapy.3,8,9
Atopic dermatitis negatively impacts health-related quality of
life (HRQoL), sleep quality, mental health and work
productivity,10–12 with greater disease severity associated with
greater work and activity impairment.10,12,13 The effect of AD
on mood and sleep disorders, HRQoL and work productivity
has been reported to be similar to that of psoriasis;12 however,
the burden of illness in AD is still a relatively understudied area.
Pruritus is a key contributor to the burden of AD, and continu-
ous itching leads to loss of sleep, reduced HRQoL and symp-
toms of depression, as well as impacting daily functioning
including the ability to work and study.11,14
Nemolizumab is an anti-IL-31 receptor A humanized mono-
clonal antibody that blocks IL-31-mediated signaling. In addi-
tion to stimulating pruritus, IL-31 also has a role in
perpetuation of the inflammatory response and dysregulation
of the physical and functional properties of the skin bar-
rier,5,15,16 both of which contribute to ongoing disease.
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Nemolizumab demonstrated improvements in pruritus, disease
severity and sleep disturbance in a phase II, 12-week, random-
ized, double-blind, placebo-controlled, dose-finding study (Part
A) in adults with moderate to severe AD inadequately con-
trolled by topical treatments (XCIMA study; NCT 01986933).17
A double-blind, 52-week extension study (Part B) demon-
strated that nemolizumab was associated with clinically mean-
ingful reductions in pruritus and dermatitis when administrated
for up to 64 weeks.18 Nemolizumab was also well tolerated,
with no new safety concerns identified with long-term use.17,18
To date, work productivity in patients with AD has not been
well studied. Therefore, the objective of the current post-hoc
analysis was to investigate the effects of nemolizumab on work
productivity and activity impairment (WPAI) in patients with
moderate to severe AD in the 12-week, placebo-controlled
study (Part A) and subsequent long-term extension (Part B)
using the Work Productivity and Activity Impairment – Atopic
Dermatitis (WPAI-AD) questionnaire as the assessment index.
We also evaluated the relationship between WPAI and indica-
tors of disease severity to identify clinical outcomes associated
with ability to work and daily activity.
METHODS
Study design
Details of the study design have been reported previously.17,18
Briefly, Part A was an evaluation of four nemolizumab dose
regimens (0.1, 0.5 or 2.0 mg/kg s.c. every 4 weeks [Q4W] or
2.0 mg/kg s.c. every 8 weeks [Q8W]). In Part B, patients
receiving nemolizumab in Part A continued the same dose and
patients randomized to placebo in Part A were re-randomized
to nemolizumab (0.1, 0.5 or 2.0 mg/kg Q4W) in a 1:1:1 ratio
(re-randomized patients were not included in the current analy-
sis).
The study was performed in accordance with the guidelines
for Good Clinical Practice and the Declaration of Helsinki. All
study documents and procedures were approved by the
appropriate ethics committee and institutional review board
(IRB) at each study center (IRB protocol approval no. QUI1-13-
404; dated 28 October 2013 for site of principal investigator),
and written informed consent was provided by all patients. The
trial registration number is NCT 01986933.
Patients
Key inclusion criteria for Parts A and B have been described
previously.17,18 Eligible patients were 18–65 years of age with
moderate to severe AD inadequately controlled by topical
corticosteroids or topical calcineurin inhibitors, with an
Eczema Area and Severity Index (EASI) score of 10 or more,
pruritus visual analog scale (VAS) score of 50 mm or more
and static Investigator’s Global Assessment (sIGA) score of 3
or more. The WPAI-AD questionnaire was administrated to
patients in the USA and Japan only, owing to limited avail-
ability of local language versions of the WPAI-AD question-
naire.19 Patients were required to have available WPAI-AD
data from baseline and subsequent visits to be eligible for
the current analysis.
Study assessments
The WPAI – Specific Health Problem (WPAI-SHP) question-
naire,19,20 developed to assess the impact of specific condi-
tions on the ability to work and perform regular daily activities,
was adapted for use in AD. The questionnaire has four
domains: (i) Work Time Missed (absenteeism); (ii) Percent
Impairment While Working (presenteeism); (iii) Percent Overall
Work Impairment; and (iv) Percent Activity Impairment.19,20
Percent overall work productivity loss is calculated based on
absenteeism and presenteeism using the formula: absen-
teeism + (% of time worked 9 presenteeism). Notably, percent
overall work impairment only targets the working population,
while activity impairment targets both the working and non-
working population.
When completing the WPAI-AD questionnaire, patients
were asked to consider the last 7 days prior to the study
visit. WPAI-AD (expressed as percentage of impairment, with
higher numbers indicating greater impairment and lesser pro-
ductivity) and Dermatology Life Quality Index (DLQI) (mea-
sured on a scale of 0–30, with higher scores representing
greater impairment) were completed by patients every
4 weeks throughout the total study period (Parts A and B).
Pruritus VAS (which ranges from 0 [no itch] to 100 mm [worst
imaginable itch]) and sleep disturbance VAS (which ranges
from 0 [no sleep loss] to 100 mm [inability to sleep at all])
were completed by patients once daily during Part A, and
every 7 days during Part B. EASI (which ranges from 0–72,
with higher scores indicating worse disease severity) was
measured at each study visit during Parts A and B. On days
with study visits, patient-reported outcome assessments were
completed prior to other study assessments. Patients were
evaluated by the same assessor at all visits for consistency
(when possible) and assessor training was employed to mini-
mize variation across study sites.
Study end-points
Work Productivity and Activity Impairment - Atopic Dermatitis
was an exploratory end-point in the study; primary and sec-
ondary efficacy end-points have been previously
described.17,18 Briefly, the primary end-point was percentage
improvement from baseline in pruritus VAS score, and sec-
ondary end-points included changes from baseline in EASI
score, SCORing Atopic Dermatitis score, sIGA, body surface
area affected by AD and sleep disturbance VAS.
Statistics
Analyses were performed in the WPAI-AD subgroup of the
intent-to-treat (ITT) population (all randomized patients who
received at least one dose of placebo or nemolizumab in Part
A or B and had ≥1 post-dose efficacy assessment). All WPAI
analyses were performed as described for the primary and
secondary end-point analyses.17 Patients enrolled into the
exploratory arm (nemolizumab 2.0 mg/kg Q8W) and all data
collected during or after rescue therapy were excluded from
analyses of Part A. Missing data were imputed using the last
observation carried forward method for analyses from Part A
(placebo controlled). In analyses of the total study period
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(Parts A and B), all data during and after administration of res-
cue therapy were included and no data imputation was
applied. Patients receiving nemolizumab 2.0 mg/kg Q8W were
included in analyses of total study period only. Patients ran-
domized to placebo in Part A were excluded from analyses of
the total study period (Parts A and B). ANCOVA for each
domain of WPAI individually, adjusted for baseline WPAI-AD
score and region, was performed to estimate the least squares
mean change from baseline in WPAI-AD scores at week 12 in
the nemolizumab 0.1, 0.5 and 2.0 mg/kg Q4W groups versus
the placebo group. As the analyses were exploratory, adjust-
ments for multiple testing were not applied. To identify clinical
outcomes which may correspond with work productivity in AD,
Pearson correlation analysis was performed in patients receiv-
ing nemolizumab (0.1, 0.5 or 2.0 mg/kg Q4W) to assess the
relationship between improvement from baseline at week 12 in
WPAI-AD scores and improvement from baseline at week 12
in dermatitis score (EASI) or patient-reported outcomes (pruri-
tus VAS, sleep disturbance VAS and DLQI). To further assess
the impact of pruritus on work and activity impairment, WPAI-
AD scores were evaluated in patients receiving nemolizumab
Q4W (0.1, 0.5 or 2.0 mg/kg) with 50% or more improvement
from baseline at week 12 in pruritus VAS score (high-respon-
ders) versus patients with less than 50% improvement from
baseline at week 12 in pruritus VAS score (low-responders and
non-responders). Statistical analyses were performed using
SAS software, version 9.2 (TS2M3; SAS Institute, Cary, NC,
USA).






Q4W (n = 28)
0.5 mg/kg
Q4W (n = 28)
2.0 mg/kg
Q4W (n = 27)
2.0 mg/kg
Q8W (n = 27)
Nemolizumab
total (n = 110)
Patients, n (%)
USA 12 (43) 12 (43) 12 (43) 11 (41) 12 (44) 47 (43)
Japan 16 (57) 16 (57) 16 (57) 16 (59) 15 (56) 63 (57)
Male sex, n (%) 14 (50) 13 (46) 14 (50) 18 (67) 11 (41) 56 (51)
Age, years 39  13.0 32  10.9 35  11.1 38  11.3 35  12.5 35  11.5
Weight, kg 73  24.3 73  25.2 73  22.4 72  17.0 70  22.1 72  21.6
Pruritus VAS, mm 78  12.9 78  11.2 77  12.1 78  11.1 78  11.8 78  11.4
EASI score 31  16.1 35  17.5 31  18.5 31  12.6 30  16.1 32  16.2
Body surface area affected, % 45  31.5 57  29.5 50  30.9 59  24.2 51  29.3 54  28.5
sIGA score, n (%)
3 13 (46) 9 (32) 12 (43) 10 (37) 14 (52) 45 (41)
4 13 (46) 11 (39) 12 (43) 14 (52) 9 (33) 46 (42)
5 2 (7) 8 (29) 4 (14) 3 (11) 4 (15) 19 (17)
DLQI 15  5 15  6 14  6 15  6 15  8 15  6
Sleep disturbance VAS 65  23 68  21 65  22 65  23 66  22 66  22
WPAI-AD
Employed, n (%) 20 (71) 20 (71) 22 (79) 19 (70) 23 (85) 84 (76)
Percent Work Time Missed† 1  4.6 5  8.8 12  29.4 2  5.8 11  25.0 8  20.6
Percent Impairment While Working† 52  27.6 61  26.8 53  28.3 55  25.3 51  28.9 55  27.1
Percent Overall Work Impairment† 53  27.2 62  26.0 53  28.6 56  25.1 53  30.2 56  27.4
Percent Activity Impairment 63  23.6 69  25.7 59  27.5 62  28.0 65  29.0 64  27.5
Data are reported as mean  standard deviation, unless otherwise stated. †Patients employed at baseline. DLQI, Dermatology Life Quality Index;
EASI, Eczema Area and Severity Index; ITT, intent-to-treat; Q4W, every 4 weeks; Q8W, every 8 weeks; sIGA, static Investigator’s Global Assessment;
VAS, visual analog scale; WPAI-AD, Work Productivity and Activity Impairment – Atopic Dermatitis.














Percent Work Time Missed
n 14 18 17 16
LSmean 4.93 3.98 1.72 1.62
SE 4.48 3.91 4.15 4.17
P† 0.1387 0.2875 0.2892
Percent Impairment While Working
n 13 18 15 16
LSmean 16.48 15.82 24.12 34.32
SE 7.08 5.99 6.51 6.35
P† 0.9438 0.4309 0.0666
Percent Overall Work Impairment
n 13 18 15 16
LSmean 16.58 16.32 23.14 34.50
SE 7.07 5.97 6.49 6.32
P† 0.9778 0.4974 0.0646
Percent Activity Impairment
n 22 26 25 24
LSmean 10.86 13.40 23.50 41.88
SE 5.69 5.27 5.34 5.46
P† 0.7446 0.1089 0.0002
†P-value compared with placebo. LSmean, least square mean; Q4W,
every 4 weeks; Q8W, every 8 weeks; SE, standard error; WPAI, Work
Productivity and Activity Impairment.
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RESULTS
Patients
Participant flow through study Part A and Part B has been pre-
viously reported.18 Of the 264 patients in the ITT population,
138 who received placebo or nemolizumab in Part A had avail-
able WPAI-AD data and were included in the current analysis
(Table 1). Of these, 111 patients completed Part A, 95 partici-
pated in Part B and 59 completed Part B. Patient baseline
demographics and clinical characteristics in the ITT WPAI-AD
subgroup were similar to those of the overall study popula-
tion,17 and 104 patients were employed at baseline. While
patients reported low baseline absenteeism (mean Percent
Work Time Missed, range 1–12%), which was comparable with
patients with moderate to severe AD and patients with other
moderate to severe diseases (plaque psoriasis, rheumatoid
arthritis and asthma) reported elsewhere,10,21–23 they reported
greater baseline presenteeism (mean Percent Overall Work
Impairment, range 53–62%) and impairment when performing
daily activities (mean Percent Activity Impairment, range 59–
69%), suggesting a high burden of disease in this patient pop-
ulation.
Improvement from baseline in WPAI-AD scores
At week 12, patients receiving nemolizumab Q4W demonstrated
greater least squares mean (standard error) decrease from base-
line (i.e. improvement) in WPAI-AD scores compared with
Patients (n)
Placebo 19 13 14 14
0.1 mg/kg 19 18 18 18
0.5 mg/kg 22 19 18 17
2.0 mg/kg 19 14 17 16























































(a) Percent work time missed
Patients (n)
Placebo 19 12 13 13
0.1 mg/kg 19 18 18 18
0.5 mg/kg 20 17 16 15
2.0 mg/kg 19 14 17 16
Baseline Week 4 Week 8 Week 12
(c) Percent overall work impairment
Patients (n)
Placebo 19 12 13 13
0.1 mg/kg 19 18 18 18
0.5 mg/kg 21 17 17 15
2.0 mg/kg 19 14 17 16
Baseline
Placebo (N = 28)
Nemolizumab, 0.1 mg/kg Q4W (N = 28)
Nemolizumab, 0.5 mg/kg Q4W (N = 28)
Nemolizumab, 2.0 mg/kg Q4W (N = 27)
Week 4 Week 8 Week 12
Baseline Week 4 Week 8 Week 12
(b) Percent impairment while working
Patients (n)
Placebo 28 22 22 22
0.1 mg/kg 28 25 26 26
0.5 mg/kg 27 25 25 25
2.0 mg/kg 27 24 24 24



















Figure 1. Change from baseline in WPAI-AD scores at weeks 4, 8 and 12 for nemolizumab compared with placebo. (a) Percent
Work Time Missed. (b) Percent Impairment While Working. (c) Percent Overall Work Impairment. (d) Percent Activity Impairment.
Data show mean  standard error. Q4W, every 4 weeks; WPAI-AD, Work Productivity and Activity Impairment – Atopic Dermatitis.
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patients receiving placebo (Table 2). Improvement from baseline
in WPAI-AD scores was observed from week 4 (Fig. 1). Improve-
ments in WPAI-AD work and activity impairment domain scores
observed at week 12 were sustained up to week 64 in patients
receiving nemolizumab Q4W and Q8W (Fig. 2).
Correlation between WPAI-AD and disease severity
Patients with available WPAI-AD data demonstrated improve-
ment from baseline at week 12 in pruritus VAS, EASI, sleep
disturbance VAS and DLQI, which are indicators of disease
severity (Fig. 3). Pearson correlation analysis revealed a strong
positive relationship between percent change from baseline at
week 12 in WPAI-AD scores and that of pruritus VAS (WPAI-
AD activity impairment and work domains, r = 0.53–0.75) and
sleep disturbance VAS (WPAI-AD work and activity impairment
domains, r = 0.64–0.70) (Fig. 4). Moderate positive correlations
were also observed between percent change from baseline at
week 12 in WPAI-AD scores and that of EASI (WPAI-AD work
and activity impairment domains, r = 0.37–0.41) and DLQI




0.1 mg/kg Q4W 19 15 13 14 10 10
0.5 mg/kg Q4W 22 17 12 11 11 11
2.0 mg/kg Q4W 19 18 13 13 13 12
2.0 mg/kg Q8W 21 17 13 11 7 7

























0.1 mg/kg Q4W 19 15 13 14 10 10
0.5 mg/kg Q4W 21 16 12 11 11 11
2.0 mg/kg Q4W 19 18 13 13 13 12
2.0 mg/kg Q8W 21 17 14 11 7 7





















(b) Percent impairment while working
60
Patients (n)
0.1 mg/kg Q4W 28 21 18 17 15 14
0.5 mg/kg Q4W 27 23 14 13 13 12
2.0 mg/kg Q4W 27 24 17 16 14 13
2.0 mg/kg Q8W 27 22 18 14 10 10


























0.1 mg/kg Q4W 19 15 13 14 10 10
0.5 mg/kg Q4W 20 16 12 11 11 11
2.0 mg/kg Q4W 19 18 13 13 13 12
2.0 mg/kg Q8W 21 17 13 11 7 7





















(c) Percent overall work impairment
Nemolizumab, 0.1 mg/kg Q4W (N = 28)
Nemolizumab, 0.5 mg/kg Q4W (N = 28) 
Nemolizumab, 2.0 mg/kg Q4W (N = 27)
Nemolizumab, 2.0 mg/kg Q8W (N = 27) Total (N = 110)
Figure 2. Absolute WPAI-AD scores at baseline and weeks 12, 24, 36, 48 and 64 for nemolizumab. Patients who were randomized
to placebo in Part A of the study were excluded from analysis of the total period (Part A and B). (a) Percent Work Time Missed. (b)
Percent Impairment While Working. (c) Percent Overall Work Impairment. (d) Percent Activity Impairment. Data show mean  stan-
dard error. Q4W, every 4 weeks; Q8W, every 8 weeks; WPAI-AD, Work Productivity and Activity Impairment – Atopic Dermatitis.
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0.34). Pearson correlation analysis of absolute change from
baseline in WPAI-AD scores demonstrated a similar trend
(Fig. S1).
Improvement from baseline in WPAI-AD scores in
high-responders versus low-responders or non-
responders
Of the 83 patients receiving nemolizumab Q4W (0.1, 0.5 or
2.0 mg/kg), 29 with work-related WPAI-AD data and 36
with general activity impairment data were defined as
high-responders. A similar number of patients were consid-
ered low-responders or non-responders (26 and 38,
respectively). High-responders demonstrated greater
improvement in WPAI-AD scores across all four domains,
compared with low-responders or non-responders (Fig. 5).
Of the 28 patients receiving placebo, the number of
patients considered high-responders was too low for
meaningful comparison: four or less patients defined as





Placebo 27 22 22 22
0.1 mg/kg 28 26 26 26
0.5 mg/kg 28 26 26 26















































(c) Sleep disturbance VAS
Patients (n)
Placebo 28 23 23 23
0.1 mg/kg 28 26 26 26
0.5 mg/kg 28 26 26 26
2.0 mg/kg 27 24 24 24




Placebo 27 22 22 22
0.1 mg/kg 28 26 26 26
0.5 mg/kg 28 26 26 26















































Placebo 28 22 22 22
0.1 mg/kg 28 26 26 26
0.5 mg/kg 28 26 26 26
2.0 mg/kg 27 24 24 24
Baseline Week 4 Week 8 Week 12
(b) EASI
(d) DLQI
Placebo (N = 28)
Nemolizumab, 0.1 mg/kg Q4W (N = 28)
Nemolizumab, 0.5 mg/kg Q4W (N = 28)
Nemolizumab, 2.0 mg/kg Q4W (N = 27)
Figure 3. Percent change from baseline in pruritus VAS, EASI, sleep disturbance VAS and DLQI at weeks 4, 8 and 12 in patients
with available WPAI data. (a) Pruritus VAS. (b) EASI. (c) Sleep Disturbance VAS. (d) DLQI. Data show mean  standard error. DLQI,
Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; Q4W, every 4 weeks; VAS, visual analog scale; WPAI, Work
Productivity and Activity Impairment.
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(c) Sleep Disturbance VAS
r = 0.03
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r = 0.29
Percent activity impairment (n = 49)
Percent change from baseline (Pruritus VAS) Percent change from baseline (EASI)
Percent change from baseline (Sleep Disturbance VAS) Percent change from baseline (DLQI)
Figure 4. Pearson correlation to assess percent change from baseline at week 12 in WPAI-AD scores and percent change from
baseline at week 12 in pruritus VAS, EASI, sleep disturbance VAS and DLQI scores in patients receiving nemolizumab 0.1, 0.5 or
2.0 mg/kg Q4W. (a) Pruritus VAS. (b) EASI. (c) Sleep Disturbance VAS. (d) DLQI. DLQI, Dermatology Life Quality Index; EASI,
Eczema Area and Severity Index; Q4W, every 4 weeks; VAS, visual analog scale; WPAI-AD, Work Productivity and Activity Impair-
ment – Atopic Dermatitis.
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DISCUSSION
Nemolizumab-treated patients with moderate to severe AD
reported numerically greater improvement in work productivity
and ability to perform daily activities compared with patients
receiving placebo in this 12-week, randomized phase II study.
Improvement in the ability to perform non-work-related regular
activities was most markedly observed for patients receiving
nemolizumab 2.0 mg/kg Q4W versus placebo, although it
should be emphasized that this was an exploratory analysis
with no formal testing planned to compare groups; therefore,
no inferences can be drawn from the statistical analyses. Over-
all, improvements in WPAI-AD were observed after 4 weeks of
therapy and sustained for up to 64 weeks and our findings
suggest that, of the AD symptoms evaluated here, pruritus and
sleep disturbance most negatively impacted WPAI-AD. Disease
severity and HRQoL also impaired WPAI-AD but to a lesser
extent. These findings build on prior studies which
demonstrate that pruritus, as the dominant symptom of AD,
contributes to sleeplessness and reduced HRQoL in patients
with AD.11,14,24,25 As pruritus is a subjective symptom, it is dif-
ficult to distinguish the effect on other clinical outcomes, even
in patients with significant improvement. Therefore, it is impor-
tant to assess the effect on functional outcomes such as work
productivity and daily activity. Our analysis identified significant
improvement in high-responders in WPAI-AD scores across all
four domains compared with low-responders which suggests
that improvement in pruritus by nemolizumab can lead to
preferable effects on other functional outcomes. This reinforces
the importance of alleviating pruritus in AD and highlights the
broader impact of the disease on patient functioning in the
workplace and daily life.
In addition to the impact on HRQoL, skin disorders are
associated with substantial economic burden. A comprehen-
sive study into the economic impact of skin diseases in the

















































High-responders 29 26 27 26
Low/non-responders 26 25 26 25











(a) Percent work time missed
Patients (n)
High-responders 28 25 27 25
Low/non-responders 26 24 25 24
–45











(b) Percent impairment while working
Patients (n)
High-responders 28 25 26 25
Low/non-responders 25 24 25 24
Baseline Week 4 Week 8 Week 12
(c) Percent overall work impairment
Patients (n)
High-responders 36 36 36 36
Low/non-responders 38 37 38 38
Baseline Week 4 Week 8 Week 12
(d) Percent activity impairment
High-responders Low/non-responders
Figure 5. Change from baseline in WPAI-AD scores at weeks 4, 8 and 12 in high-responders (patients receiving nemolizumab Q4W
with 50% or more improvement from baseline at week 12 in pruritus VAS score) and low-responders or non-responders. (a) Percent
Work Time Missed. (b) Percent Impairment While Working. (c) Percent Overall Work Impairment. (d) Percent Activity Impairment.
Data show mean  standard error. Q4W, every 4 weeks; VAS, visual analog scale; WPAI-AD, Work Productivity and Activity Impair-
ment – Atopic Dermatitis.
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2004 at $US39.3 billion.26 This total included $US10.2 billion in
lost productivity costs accounting for missed time from work to
seek medical care, impaired ability to work and lost future
earnings owing to premature death.26 Patients with AD incur
significantly greater health-care resource use and direct costs
versus individuals without AD, with the cost burden rising with
increasing disease severity.27,28 While calculating the total
direct and indirect costs of AD is challenging as it is a common
disease with a broad spectrum of severity, the total annual
financial burden associated with AD in the USA in 2004 was
estimated at $US4.2 billion, the equivalent of $US5.3 billion in
2015.26,29 This value does not include costs associated with
presenteeism or work time missed due to reasons other than
medical visits that are commonly associated with AD.26,29 The
same study reported the corresponding financial burden in
2004 associated with psoriasis at the lower cost of $US3.7 bil-
lion.26,29 Using WPAI data from a phase III study investigating
the impact of adalimumab on moderate to severe psoriasis,
Kimball et al.30 estimated the potential annual indirect cost
savings for employers associated with reduction in work pro-
ductivity impairment owing to psoriasis at approximately
$US4500 per full-time employed patient, corresponding to an
11.1% improvement in work productivity impairment versus
placebo, indicating the potential productivity benefits for
patients with AD.
Presenteeism is a major contributor to productivity loss, with
evidence to suggest it has a greater economic impact than
absenteeism.31–33 Our patients reported high levels of presen-
teeism at baseline; more than half of their work productivity
and daily activities were impaired compared with those in prior
studies of moderate to severe AD and other moderate to sev-
ere skin disorders,10,21,34 suggesting a high burden of disease.
Patients with high levels of impairment may therefore have the
potential to derive economic benefits associated with nemoli-
zumab therapy and the alleviation of pruritus.
The study has a number of limitations to consider when
evaluating the findings. These include the small sample size
and the absence of a placebo arm in Part B, which might have
introduced bias owing to administration of only active drug.
The WPAI-AD was only assessed in the USA and Japan and
may not be generalizable to patients from other countries. A
difference in work culture between Japan and the USA may
have also impacted study findings. Patient-reported absen-
teeism and presenteeism were not validated against employ-
ment records, and information regarding employment status
(full-time, part-time, job type) was unavailable.
In summary, nemolizumab-treated patients with moderate to
severe AD inadequately controlled by topical treatments
reported sustained improvements in work productivity and
daily activities. Nemolizumab-associated improvement in pruri-
tus and pruritus-associated sleep disturbance could lead to
reduced productivity-related burden in AD.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Pearson correlation to assess absolute change from
baseline at week 12 in WPAI-AD scores and percent change
from baseline at week 12 in pruritus VAS, EASI, sleep distur-
bance VAS and DLQI scores in patients receiving nemolizumab
0.1, 0.5 or 2.0 mg/kg Q4W. (a) Pruritus VAS. (b) EASI. (c) Sleep
disturbance VAS. (d) DLQI. DLQI, Dermatology Life Quality
Index; EASI, Eczema Area and Severity Index; Q4W, every
4 weeks; VAS, visual analog scale; WPAI-AD, Work Productiv-
ity and Activity Impairment – Atopic Dermatitis.
Table S1. List of investigators in the USA and Japan
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